NCT06101485

Brief Summary

This project has focus on patients with atrial fibrillation testing a telerehabilitation program for patients with atrial fibrillation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
208

participants targeted

Target at P50-P75 for not_applicable atrial-fibrillation

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 26, 2023

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 26, 2023

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

October 26, 2023

Status Verified

October 1, 2023

Enrollment Period

2.1 years

First QC Date

June 26, 2023

Last Update Submit

October 24, 2023

Conditions

Keywords

TelerehabilitationQuality of lifeCardiac patientsAtrial fibrillation

Outcome Measures

Primary Outcomes (1)

  • Changes in AF specific health-related quality of life

    The Atrial Fibrillation Effect on quality of life questionnaire (AFEQT) is a 20-item self-administered questionnaire designed to assess the impact of AF on the patients' health-related quality of life (HRQoL) across symptoms, daily activities, treatment concerns, and treatment satisfaction. Scores range from 0-100, with higher scores indicating better HRQoL

    For both intervention and control group: QoL will be measured at baseline, end of telerehabilitation (16 weeks) and after 28 weeks

Secondary Outcomes (25)

  • Changes in AF knowledge

    For both intervention and control group: To be measured at baseline, end of telerehabilitation (16 weeks) and after 28 weeks

  • Measurement of weight

    Intervention group: Weight will be measured at baseline, twice a week, and as needed up to 16 weeks

  • Measurement of bloodpressure

    Intervention group: Bloodpressure will be measured at baseline, twice a week, and as needed up to 16 weeks

  • Measurement of pulse

    Intervention group: Pulse will be measured at baseline, everyday, and as needed up to 16 weeks

  • Measurement of steps

    Intervention group: Steps will be measured from the date of randomization, everyday to end follow up (28 weeks)

  • +20 more secondary outcomes

Study Arms (2)

Telerehabilitation group

EXPERIMENTAL

The telerehabilitation group (n=104) will participate in the FP-AF program for 16 weeks. The program is administered by the AF clinics and the healthcare centers (HC) in Viborg, Skive and Silkeborg Municipalities. After enrollment, the patients will have an individual meeting with the project nurse. Here the patient (and relatives, if necessary) will be instructed in the use of the technologies and an individual plan will be formulated for the AF patient's telerehabilitation. After participation in 16 weeks the patients start a 12 weeks follow-up period, where they will only measure steps and have access to the Heartportal on their own devices.

Device: Telerehabilitation

Conventional rehabilitation

NO INTERVENTION

The control group (n=104) will follow the conventional care regime in the AF clinic and will not have contact to the project nurse. When the AF patients are in a stable condition, they will be followed by their general practitioner (GP). The control group will be in the study for 28 weeks.

Interventions

Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)

Telerehabilitation group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with atrial fibrillation
  • Adults over 18 years
  • Living in Skive, Viborg or Silkeborg Municipalities
  • Living at home and capable of caring for themselves
  • Have basic computer skills or having a relative/friend with basic computer skills

You may not qualify if:

  • Pregnancy
  • Refusal or inability to cooperate; or patient not does not speak, read or understand Danish
  • Life expectancy less than a year

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central Jutland Regional Hospital

Viborg and Silkeborg, Denmark

RECRUITING

Related Publications (1)

  • Dinesen B, Albertsen AE, Joensen EDR, Spindler H, Jensen KM, Kidholm K, Frost L, Dittman L, Gunasegaram M, Johnsen SP, Jochumsen MR, Svenstrup D. Future Patient-Telerehabilitation of Patients With Atrial Fibrillation: Protocol for a Multicenter, Mixed Methods, Randomized Controlled Trial. JMIR Res Protoc. 2025 Feb 18;14:e64259. doi: 10.2196/64259.

Related Links

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Telerehabilitation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

RehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and ServicesTelemedicineDelivery of Health CarePatient Care ManagementHealth Services Administration

Study Officials

  • Birthe Dinesen, MSc, Ph.D

    Aalborg University

    PRINCIPAL INVESTIGATOR
  • Dorthe Svenstrup, MD, Ph.D

    Central Jutland Regional Hospital, Viborg

    STUDY DIRECTOR
  • Lars Frost, MD, Ph.D, DMSc

    Central Jutland Regional Hospital, Silkeborg

    STUDY DIRECTOR

Central Study Contacts

Birthe Dinesen, MSc, Ph.D

CONTACT

Dorthe Svenstrup, MD, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomised controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 26, 2023

First Posted

October 26, 2023

Study Start

January 1, 2023

Primary Completion

February 1, 2025

Study Completion

June 30, 2025

Last Updated

October 26, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

No plan for sharing protocol as we are applying for patent.

Locations